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Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a group of tumours, 
which originate from the neuroendocrine system. GEP-NETs are characterized by over-
expression of somatostatin receptors and can therefore be targeted using radiolabelled 
somatostatin analogues for peptide receptor radionuclide therapy (PRRT). The Lutetium-
177 labelled somatostatin analogs DOTA-TOC and DOTA-TATE are being increasingly 
used for PRRT. The radioactive Lutetium-177 destroys tumor cells by emitting ionizing 
radiation. Unfortunately, also normal healthy organs express somatostatin receptors and 
thus the PRRT can cause significant radiation load to normal tissue. In order to protect 
the healthy organs and to maximize the radiation dose of the tumors radionuclide thera-
pies need to be planned well by doing individual dosimetry.   
 Tumor dosimetry requires segmentation of the tumors from the background. Con-
ventionally this segmentation has been performed manually, but the manual segmentation 
is often very dependent on skills of the operator who is doing the segmentation and it 
might not be very reproducible. These problems can be avoided with the use of automatic 
segmentation methods. Even though automatic segmentation has lately been a hot topic 
in positron emission tomography (PET) these methods have not been studied in PRRT.  
In this Master of Science thesis automatic segmentation methods were studied 
from the PRRT perspective. Four segmentation methods were chosen to be evaluated: 
thresholding, k-means clustering, fuzzy-c-means clustering and expectation maximiza-
tion. The evaluation was performed using simulated and real clinical single photon emis-
sion computed tomography (SPECT) images acquired during PRRT. The segmentation 
methods were compared with the help of Dice similarity coefficient (DSC), Classification 
error (CE) and the integral of the time activity curve. 
The results state that expectation maximization is the most accurate algorithm of 
the four tested methods. It maximizes DSC and minimizes CE with every phantom.  
Thresholding gave promising results, but the optimal thresholding values had to be sought 
for each phantom, which made the method time-consuming. K-means clustering and 
fuzzy-c-means clustering were less successful. The accuracy of the methods with patient 
data is hard to estimate, due to the lack of the ground truth. However, the results with the 
patient data are very similar to the results obtained with the phantom data and they showed 
that segmentation has a big impact on the calculated tumor dose. 
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Gastroenteropankreaaliset neuroendokriiniset kasvaimet ovat lähtöisin neuroendokriini-
sestä järjestelmästä. Kasvaimet ylituottavat somatostatiinireseptoreita, mistä johtuen ne 
voidaan kohdentaa peptidireseptoriradionuklidihoidoissa (PRRT) käyttäen radioleimat-
tuja somatostatiinianalogeja. Lutetium-177 leimattujen somatostatiinianalogien DOTA-
TOC ja DOTA-TATE käyttö PRRT:ssa on lisääntynyt. Radioaktiivinen lutetium-177 tu-
hoaa kasvainsoluja emittoimalla ionisoivaa säteilyä. Valitettavasti myös terveet kudokset 
sisältävät somatostatiinireseptoreja. Siitä johtuen peptidireseptoriradionuklidihoidot voi-
vat aiheuttaa merkittävää säteilykuormitusta terveisiin kudoksiin. Jotta terveitä kudoksia 
pystyttäisiin suojaamaan ja kasvaimiin kohdistuvaa säteilyannosta maksimoimaan, ra-
dionuklidihoidot täytyy suunnitella tarkasti käyttäen yksilöllistä annoslaskentaa. 
Kasvaindosimetrian onnistuminen vaatii kasvainten segmentoimista taustasta. Ta-
vanomaisesti segmentointi suoritetaan käsin, mutta manuaalisegmentointi on usein erit-
täin riippuvainen käyttäjän taidoista, eikä ole toistettavissa. Ongelmat voidaan välttää au-
tomaattisten segmentointimenetelmien avulla. Vaikka automaattinen segmentointi on 
suosittu tutkimuskohde positroniemissiokuvantamisessa (PET), ei menetelmiä ole tut-
kittu PRRT:ssa. 
Tässä diplomityössä on tutkittu automaattisia segmentointimenetelmiä peptidire-
septoriradionuklidihoitojen näkökulmasta. Työhön on valittu neljä segmentointimenetel-
mää: kynnystäminen (thresholding), k-means klusterointi, fuzzy-c-means klusterointi ja 
todennäköisyyden maksimointi (expectation maximization). Menetelmien arviointi on 
suoritettu käyttäen peptidireseptoriradionuklidihoidoista saatuja rekonstruoituja SPECT 
kuvia. Työn toteutuksessa on käytetty sekä fantomi- että potilasdataa. Segmentointime-
netelmiä vertailtiin käyttäen apuna Dice similarity coefficient (DSC) ja Classification er-
ror (CE) -menetelmiä. 
Tulosten mukaan expectation maximization on tarkin neljästä segmentointimene-
telmästä. Se maksimoi DSC:n ja minimoi CE:n. Myös eri arvoilla testattu thresholding 
onnistui segmentoinnissa hyvin, mutta optimaaliset arvot täytyi etsiä, ja menetelmä osoit-
tautui aikaa vieväksi. K-means klusterointi sekä fuzzy-c-means klusterointi eivät olleet 
tarkkoja. Potilasdatatuloksien tarkkuutta on vaikea arvioida, koska referenssidata puut-
tuu. Tulokset ovat kuitenkin samankaltaisia kuin fantomidatan kanssa saadut tulokset ja 
ne osoittavat että segmentointimenetelmän valinnalla on iso vaikutus tuumorin absorboi-
tuneeseen annokseen. 
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1 INTRODUCTION 
In Finland, over 11000 people die of cancer annually [1]. In 2012, worldwide there were 
14 million new cases of cancer and about 8.2 million people died because of it [2]. Cancer 
is already the deadliest disease in the world, but it is estimated that in 2020 in Finland 
over 33 000 people get cancer and in 2050 worldwide about 25 million people get cancer 
annually [1, 2]. The amount of cancers is increasing rapidly. Partly, because of better 
diagnostics, but mostly because of the aging of the population and increased life expec-
tancy [3]. New, more reliable and better medical assistance would be a great benefit in 
the fight against cancer. Speed and accuracy are the key words. Fortunately, the technol-
ogy is developing fast, which enables new innovations also in the field of cancer treat-
ment. 
  Radionuclide therapy is not a new cancer treatment technology, but the adoption 
of peptide receptor radionuclide therapies (PRRT) in gastroenteropancreatic neuroendo-
crine tumors (GEP-NETs) has revived the interest towards radionuclide therapy. Dosim-
etry is an important and interesting part of radionuclide therapy. The treatment dose 
should be big enough to cause damage to cancer cells, but sufficiently small to avoid the 
side effect on healthy tissue. Unfortunately dosimetry is not often performed in radionu-
clide therapy to tailor patient specific treatments and many times all the patients just re-
ceive the same treatment dose. This can lead to complications because the healthy tissue 
around the tumors gets violated during the treatment periods and the tumors might not get 
the required dose to produce optimal damage [4]. 
 Dosimetry would help to identify critical organs, whose radiation dose should be 
kept in minimum and also to measure the dose to tumors whose radiation damage should 
be maximized. Tumor dosimetry partly relies on the segmentation of the tumors from the 
background organs. The segmentation of the tumors is necessary to get the tumor ab-
sorbed dose. This segmentation can be done manually, but it is time-consuming, subjec-
tive, error prone and not reproducible. Automatic segmentation methods on the other hand 
are fast, objective and often 100% reproducible [5]. Automatic methods have not been 
studied in PRRT before. 
The main focus of this Master of Science thesis is to compare four different seg-
mentation methods used for segmenting tumors from single photon emission computed 
tomography (SPECT) images used in PRRT. The segmentation methods are compared in 
two different parts. The first part includes segmenting with phantom data. There are six 
fully simulated phantoms. The phantoms model patients injected with a 177Lu-dotatate 
radiopeptide, with a tumor in the liver. Each phantom includes one tumor and the sizes of 
the tumors vary between the phantoms. The second part includes segmenting with real 
patient data. The real patient data consists of several SPECT studies performed after three 
2 
 
177Lu-dotatate treatments. These SPECT studies are the same studies, which have been 
used in actual individualized PRRT dosimetry. The aim is to find the possible differences 
between the segmentation methods. The comparison is done using three different meth-
ods: Dice similarity coefficient, Classification error and integral of the time activity curve. 
This Master of Science thesis is part of the doctoral thesis of Eero Hippeläinen, which 
aims to develop and validate a dosimetry software package for PRRT.  
The thesis consists of five chapters, the presentation and the aim of the thesis as 
the first part. Chapter 2 is a literature review of the theory behind the thesis. The used 
material and methods are introduced in the chapter 3. The results are introduced in the 
fourth chapter, and they are discussed in the fifth chapter. 
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2 BACKGROUND 
The peptide receptor radionuclide therapies are especially used for GEP-NETs. The GEP-
NETs are cancers of the neuroendocrine system, and are typically diagnosed in the gastro-
intestinal tract, lungs, liver and/or pancreas [6]. Unfortunately, different types of GEP-
NETs can be undetected for years without obvious signs or symptoms. This can cause 
delayed diagnosis, for which reason the cancer can be metastasized and the treatment gets 
more complicated. Typical symptoms depending on the source of cancer are for example 
diarrhea, asthma and/or heart palpations. Due to the common side effects, the GEP-NET 
is hard to diagnose [6, 7]. 
The GEP-NETs appear at all ages, the highest incidence being over 50 year old 
people. Typical types of GEP-NETs are for example insulinoma that makes pancreas pro-
duce too much insulin, which causes hypoglycemia, and glucagonoma, where tumor cells 
make pancreas produce large amounts of glucagon [6, 7]. 
Cancers are individual diseases; they all have their individual features (shape, 
mass, location, volume, aggressiveness and so on). Therefore, also the treatment pro-
cesses are individual. After the cancer gets diagnosed and imaged, the next step is to 
decide the most suitable treatment method. Depending on the type of the cancer, the op-
tions are radiation therapy, surgery and/or medication [8]. In this thesis, the main focus is 
in radiation therapies and the latter two are only introduced briefly. 
Depending on the aim of the treatment operation, it is either palliative or curative. 
A palliative operation relieves symptoms, while a curative operation cures or removes the 
cancer completely [3]. 
2.1 Surgical treatment 
If the tumor is localized well and the state of the patient allows, a surgical operation to 
remove the whole tumor is the main treatment method. Unfortunately, in most cases the 
surgery alone is not the perfect solution especially, if the cancer is metastatic. Therefore, 
there has to be also some other treatment method(s) involved. Combination of at least two 
types of treatment is the standard. For example, a combination of surgery and chemother-
apy. A surgical treatment treats cancer that is confined locally, while chemotherapy also 
kills the cancer cells that have spread to distant sites. Sometimes radiation therapy or 
chemotherapy is given before surgery to shrink a tumor, thereby improving the oppor-
tunity for complete surgical removal [9]. 
Advantages are that the surgery is relatively fast treatment method, and theoreti-
cally the whole cancer can be removed at once. Removal of the primary tumor is indicated 
to prevent complications such as bleeding and small bowel obstruction. Disadvantages 
are the possible complications and the need for patient to be hospitalized after the opera-
tion. Also, the operation can cause some physical and cosmetic harm [9]. 
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A surgical operation can also be used for removing a tumor just partly. If tumor 
extension is limited or localized, then segmental resection with removal of the regional 
nodes is beneficiary. If the size of the tumor is large, the rest of the cancer can be treated 
with for example radiation therapy and/or medication. Also only metastases can be re-
moved surgically, and the rest of the cancer with other methods [8]. 
2.2 Radiation therapy 
Radiation therapy is divided into two main categories: external and internal radiation ther-
apies. External beam radiotherapy focuses the radiation at the tumor from outside the 
body and internal radiation therapy is a form of treatment where a source of radiation is 
put inside the body of the patient. Approximately half of the patients diagnosed with can-
cer get radiation therapy during their treatment period [9] and about one third of all the 
cancer patients get palliative radiation therapy [3]. 
There are few dose quantities and terms that are important to know while working 
with radiation therapy and radioactive materials. These terms and their units are presented 
below. 
Activity or radioactivity is measured by the number of atoms disintegrating per 
unit time. The equation: 
 
 
where 𝑑𝑁 is the total number of radioactive atoms in a given period of time 𝑑𝑡. The minus 
sign means that the number of radioactive atoms decrease with time. The unit for the 
activity is the Becquerel. 
 
 
The activity cannot be directly converted into absorbed dose. There are several 
features of the ionizing radiation that has to be known first. For example, the type and the 
energy of the radiation. Furthermore, the effects of the ionizing radiation are different in 
different tissues. Thus, there are several features of the radiated object that has to be 
known, for example, its mass and density. 
Absorbed dose is a physical quantity to measure the radiation energy absorbed 
by unit mass of substances. Under normal circumstances, the larger the absorbed dose, 
the larger will be the hazard. The absorbed dose applies to all types of ionizing radiation 
and substances. However, the same absorbed dose for different type of radiation under 
different exposure conditions can cause different biological effects on human bodies. 
The absorbed dose D is calculated with the equation: 
 
  
 
𝐴 = −
𝑑𝑁
𝑑𝑡
   (6) 
  
 
[
1
𝑠
] = [𝐵𝑞] (𝐵𝑒𝑐𝑞𝑢𝑒𝑟𝑒𝑙)   (7) 
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𝐷 =
𝑑𝜀
𝑑𝑚
 
  
(1) 
 
where the mean energy 𝑑𝜀 is imparted by ionizing radiation to matter of mass 𝑑𝑚. [3] 
The unit for the absorbed dose is the Gray: 
 
 
 
  
[
𝐽
𝑘𝑔
] = [𝐺𝑦] (𝐺𝑟𝑎𝑦) 
  
(2) 
 
Equivalent dose measures the health effect of low levels of radiation on the hu-
man body. It takes into account the type of ionizing radiation producing the dose. It 
measures the biological effect of different types of radiation. The equivalent dose is cal-
culated with the equation: 
where 𝑤𝑅 is the radiation weighting factor and 𝐷𝑇,𝑅 is the absorbed dose in tissue T by 
radiation type R. The radiation weighting factors for different types of radiation have been 
established by the International Commission on Radiological Protection (ICRP). The 
value of 𝑤𝑅 is 1 for x-rays, gamma rays and beta particles, but higher for example for 
protons and neutrons. The SI unit for equivalent dose is also joule per kilogram, but the 
unit is the Sievert [3]. 
 
Effective dose takes into account the absorbed doses received by different organs 
and tissues and weights them according to present knowledge of the sensitivity of each 
organ to radiation. The type of radiation is also taken into account. The effective dose is 
used for example for comparing the overall health effects of different radionuclides. The 
effective dose is calculated with the equation: 
where 𝑤𝑇 is the corresponding weighting factor established by ICRP and 𝐻𝑇 is the equiv-
alent dose absorbed by tissue T. The unit of the effective dose is the Sievert [10]. 
Sufficiently high-energetic radiation causes molecular ionization that damages 
cells, and eventually causes cell death. The aim is to direct the radiation straight to tumor 
as accurate as possible. Thus, the damage of the surrounding tissue stays low [10]. 
 
 
  𝐻𝑇,𝑅 = 𝑤𝑅 × 𝐷𝑇,𝑅   (3) 
 
 
 [
𝐽
𝑘𝑔
] = [𝑆𝑣] (𝑆𝑖𝑒𝑣𝑒𝑟𝑡) 
  
(4) 
  
 
 
𝐸 = ∑[𝑤𝑇 × 𝐻𝑇]
𝑇
 
 
  (5) 
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External radiation therapy is a local treatment method, so radiation does not effect 
on the metastases outside the radiation range. Also, most of the side effects are local. 
They are mostly depending on the amount of the radiation dose, treatment duration and 
the features of the radiated part of the body. Today, skin injuries are minor. Only minor 
side effects, for example redness, dryness and/or ulcers are possible. Also, mucosae can 
be damaged, and some ulcers and eruption can be noticed at treated areas. Also, for ex-
ample diarrhea, pain, burning, tiredness and hair loss are usual. The side effects get better 
within next few weeks, but radiated areas will remain more sensitive than before the treat-
ment [9]. 
The side effects that can be noticed months or even years after treatments are 
called the late side effects. The most common late side effect is extra ligament in treated 
areas. The extra ligament feels harder than normal tissue and can cause functional harm. 
One of the worst late side effects is a new cancer. Fortunately, with modern treatment 
systems the risk is very small, about 1-3% of the patients gets this kind of cancer during 
next 20-30 years after the treatment session [9]. 
In addition to the side effects mentioned above, radiation therapy can cause also 
another kind of harm for kids. Radiation causes local growth failures, hormonal imbal-
ance and central nervous system damages. These symptoms are fortunately also rare and 
can mostly be avoided with modern equipment [9]. 
2.2.1 External radiotherapy 
External radiation therapy is the most common form of radiotherapy [3]. In external ra-
diotherapy the healthy tissue surrounding the tumor gets also some amount of radiation. 
It is a painless treatment method, which nevertheless can cause some of the side effects 
mentioned above [9]. 
Like a surgical operation, the external radiotherapy can be used either as a pallia-
tive or a curative treatment. A treatment time lasts minutes and the whole treatment period 
lasts several weeks, one treatment per weekday. The weekends are usually treatment-free. 
The treated patient does not have to stay in hospital during the whole period. The treat-
ment is fractionated, so the surrounding healthy tissue gets time to recover and the side 
effects stay minor. Conventional fractionation dose is usually about 2 Gy per treatment 
time. A palliative treatment is usually given in smaller doses and shorter periods than a 
curative treatment [3]. 
The external radiation therapy is typically delivered with a linear accelerator. The 
patient lies on a moveable treatment table and lasers are ensuring that the patient is in the 
proper position. An electron gun produces electrons, that are accelerated in a wave guide. 
There are two possibilities to continue. The accelerated electrons can either be focused 
straight to the target area or be collided with a high density x-ray target, which generates 
the photon beam. The electron beams are useful for treating skin-deep lesions because the 
maximum of dose deposition occurs near the surface. The photon beams do not lose their 
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energy as rapidly, and thus are more useful for treating tumors located deeper inside the 
body [10]. 
 With the help of a collimator the photon beam is shaped to match the wanted 
target area. A currently used collimator type is a multi-leaf collimator (MLC) that consists 
of tens of lead leaves. These leaves are individually movable, thus they can be adjusted 
to match the shape of the tumor, which will minimize the amount of healthy tissue being 
exposed to radiation [11]. 
There are also various different kinds of new external radiation therapy tech-
niques. For example such methods as the CyberKnife [12] and the Gamma Knife [13]. 
These treatment methods can deliver radiation more accurately to the target areas from 
many different angles. However, the Gamma Knife is designed especially for brain tu-
mors, and is not a useful treatment method for GEP-NETs. 
The CyberKnife consists of a small linear accelerator and a moving robotic arm 
which allows the radiation to be directed at any part of the body from any direction. Un-
fortunately, a single treatment session can be long-lasting because the radiation is given 
from several different angles [12]. Also, its primary treatment target is a small tumor with 
clear lines, which GEP-NETs rarely are. In spite of new innovative methods, the external 
radiotherapy still is not effective enough for metastatic GEP-NETs, and the radiation dose 
of the healthy tissue is larger. 
2.2.2 Internal radiotherapy 
The term internal radiation therapy usually refers to the brachytherapy. In brachytherapy 
the radiation sources are close to the tumor and the radiation dose of the healthy tissue 
stays minor [8]. 
Depending on the dose rates the radioactive source is inserted to a patient by hand 
(with a catheter or a needle) or with a computer-controlled remote afterloading machine. 
When accomplishing a low dose rate (LDR) treatment the source (for example an iridium 
wire with the activity of 37 MBq/cm) is inserted to the patient by hand. The LDR treat-
ment period lasts about 5-7 days, and the dose rate per treatment session is 0.4-2 Gy/h 
[8]. The afterloading machines are usually used with high dose rate (HDR) treatments, 
where the dose rate is over 12 Gy/h. The afterloading machine performs transfer, insertion 
and removal of the source [14]. 
A well-executed internal radiotherapy, either combined with external radiation 
therapy or alone, can produce better results than functionally extensive surgery. Other 
benefits of internal radiation therapy in relation to external radiation therapy are listed 
below: 
1. Brachytherapy is faster. The treatment shortens from 4-7 weeks to 5-7 days. 
2. Thus, it is also cheaper solution. 
3. When the radioactive source is near the tumor, the absorbed dose of healthy 
tissue is much lower [14]. 
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Brachytherapy has also some disadvantages in relation to external radiation ther-
apy. First, the operation requires a surgical operation. Thus, it is harder to execute. This 
means also that there is often need for specialists. In contrast to the external radiation 
therapy, the patient should be hospitalized after the treatment. Also, the radiation load of 
the medical personnel is problematic (especially when inserting the source(s) by hand) 
[14]. 
In spite of the need of surgical treatments the complications are minor. For exam-
ple infections and hemorrhage are uncommon. The other side effects are in relation to 
ones mentioned earlier [14]. 
Intracavitary brachytherapy has been used for decades to treat gynecological can-
cers with great results. It is also a useful treatment method for example for esophageal 
and nasopharyngeal cancers [14]. But like all the methods introduced above, the brachy-
therapy unfortunately is ineffective against metastatic GEP-NETs. 
2.3 Pharmacological treatment methods 
The three major modalities of the pharmacotherapy treatment are hormonal therapy, in-
terferon therapy and chemotherapy. Pharmacological treatment methods are usually used 
as adjuvant treatment methods.  Doses are usually taken orally or by injections. During 
treatment periods, the patient does not have to stay in hospital, but is able to live as normal 
life as it is possible with the disease [15]. 
In some cases, the cancer cells may be utilizing hormones produced by the body. 
This is prevented by certain medicines or drugs, which inhibit the production or activity 
of such hormones, and eventually stop the growth of the cancer or even cause cell death. 
The other solution is to surgically remove the endocrine organ(s) that produce(s) the par-
ticular hormone, for example the ovary, or tissue that may suffer from the hormonal ac-
tivity, for example the breast tissue [16]. 
Interferon therapy acts as the same way as the hormonal therapy, but on the con-
trary, and with the difference that the acting element is interferons, proteins produced by 
the body. As the hormone therapy reduces the amount of hormones in the body, the 
interferon therapy tries to increase the amount of proteins that are fighting against the 
cancer cells. The main focus of hormone and interferon therapies is not necessarily killing 
the cancer cells but to stop the cancer cells from multiplying [17]. 
The most common pharmacological treatment method is chemotherapy. While 
traditional radiation therapy methods and surgery aim for local treating, chemotherapy is 
more comprehensive method and tries to cure the cancer in all over the body. The 
chemotherapy can be used either palliatively or curatively. However, the main use is to 
strenghten the effectiveness of the primary treatment methods such as radiation therapy, 
and relieve symptoms in cases where the patient is diagnosed with incurable cancer. [18] 
Chemotherapy prevents cell division, which finally will lead to cell death and the 
cancer gets destroyed. Because cancer cells generally grow and divide faster than normal 
cells, they are more susceptible to the action of chemotherapy.  However, damage to 
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healthy cells is unavoidable, and this damage accounts for the side effects linked to these 
drugs [18]. 
The side effects are individual depending on the doses and the used medication. 
Common side effects are almost similar to the side effects caused by radiation therapy 
treatment methods, for example tiredness, nausea, hair loss and dryness [15]. 
2.4 Peptide receptor radionuclide therapy 
Radionuclide therapy is a form of treatment methods that is capable of treating several 
metastases at the same time, which is more or less difficult with the other treatment meth-
ods [19] Radionuclides have been used in medicine for decades in Finland. First in the 
late 1930s, radiophosphorus (32P) was used in leukemia treatments and in 1954 the Fin-
land’s first radioiodide treatment was made [20]. 
The efficacy of treatment depends on the trapping of the radionuclide to the cancer 
cell by means of its carrier, and the time of retention. The whole process is quite compli-
cated when the radionuclide follows the laws of radiation physics and radiation biology, 
the carrier follows the laws of pharmacology, and the compound of these two follows the 
laws of pharmacodynamics [20]. Basically, a radionuclide moves like a drug inside the 
body, but its therapeutic effect is based on the cancer cell-killing nature of radiation. Thus, 
radionuclide therapy cannot be clearly categorized as a form of either internal radiation 
therapy treatment or pharmacotherapy. In the literature, this is more or less a line drawn 
in water. 
Most of the radionuclide therapies are performed using radionuclides, which de-
cay by β- decay. In β- decay the extra neutron in the nucleus transforms into a proton, 
releasing negative beta radiation and a variable amount of gamma radiation [20]. The 
nucleus is converted into a nucleus with one higher atomic number while emitting an 
electron (e−) and an electron antineutrino (νe). The generic equation is: 
 
𝑁𝑍
𝐴 → 𝑁𝑍+1
𝐴 + 𝑒− + 𝑣𝑒  
 
where 𝑁𝑍
𝐴  is the parent nuclide and 𝑁𝑍+1
𝐴  is the daughter nuclide. The atomic mass A 
stays unchanged, but the atomic number Z increases by one [10]. The emitted electron is 
the beta particle. Thus, the treatment effect of the radioisotopes is based on the short-
ranged beta radiation. The range of beta particle is only a few millimeters depending on 
the energy of the emitted electrons. In addition to the beta particles the radionuclides used 
in radionuclide therapies often also emit gamma radiation which can be used in post-
treatment imaging [21]. Gamma radiation and imaging methods are introduced later in 
this thesis. 
Usually, the radiopharmaceutical consists of a radionuclide, its biologically active 
carrier and their bond, but not always. For example, radioiodide (131I) does not need a 
carrier. The most used isotopes in radionuclide therapies are Iodide-131 (131I), Yttrium-
90 (90Y), Lutetium-177 (177Lu) and Samarium-153 (153Sm). They differ in half-life, decay 
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energies and the amount of emitted gamma radiation [20]. 177Lu, the radionuclide studied 
in this thesis, emits about 80% beta-radiation and about 20% gamma-radiation per decay 
[22]. 
PRRT is a relatively new treatment method. The first PRRT was made in 1996 in 
Switzerland. Currently, it is the most viable treatment method for GEP-NETs. PRRT is 
based on the use of somatostatin analogs. In GEP-NETs, the somatostatin analogs bind 
to somatostatin receptors. There are three radionuclides that are attached to somatostatine 
analogs to create radiopeptides: Indium-111 (111In), 90Y and 177Lu of which 111In is only 
used for imaging [21]. 
177Lu decays by simultaneously transmitting heavily ionizing beta (β-) radiation 
that destroys GEP-NETs and gamma radiation which can be imaged outside the body 
with a gamma camera. The binding sites can be determined with the SPECT images and 
that information can be used for dose calculation. The half-life of 177Lu is 6.7 days and 
its beta particles have a range of 2 mm in soft tissue making it a good candidate for PRRT 
[22]. Tissue penetration is an important factor since a certain range of radiation is neces-
sary to kill tumor cells but not damage surrounding, healthy tissues [21]. 
Dotatate is an amide of the acid DOTA and (Tyr3)-octreotate, a derivative of oc-
treotide. DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, 
(CH2CH2NCH2CO2H)4, acts as a chelator for a radionuclide. (Tyr
3)-octreotate binds to 
somatostatin receptors, which are found on the cell surfaces of a number of neuroendo-
crine tumors. Dotatate can be tagged with 177Lu [21]. Structural formula of the 177Lu-
dotatate is presented in figure 1. 
 
 
Figure 1: The structural formula of 177Lu-dotatate. Adopted from [22]. 
 
Unfortunately, the somatostatin-based radiopharmaceutical does not bind only to 
the tumor cells, because also many normal organs express somatostatin receptors. Thus, 
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radionuclide therapies should be planned well so that the amount of radioactivity is max-
imized in tumors and minimized in critical. The treatment is performed over multiple 
cycles, usually administered 8-12 weeks apart. Dosing of 177Lu is currently recommended 
at 7.4GBq/m2 [21]. 
The results of 177Lu-dotatate treatments have been promising. Not only the tumor 
sizes have been decreasing, but the total lifetime of the patient has been increasing and 
also the quality of life of the patients has improved. 177Lu-dotatate has a particularly fa-
vorable affinity profile. Its maximum tolerated dose is limited by toxic effects especially 
on the kidney and bone marrow, and results seem encouraging compared with historical 
therapeutic data. The most common side effects of 177Lu-dotatate treatments are gastro-
intestinal comprising abdominal pain, nausea or diarrhea that are commonly transient 
[21]. 
In spite of the promising results, the 177Lu-treatments are not yet globally estab-
lished. The lack of accurate dosimetry might be one of the reasons for this.  177Lu-treat-
ments are currently often based on coarse approximation of the absorbed doses and con-
servative dose limits for the critical organs. Randomized studies of peptide-receptor radi-
onuclide therapy are lacking, making comparison of published data difficult [23]. 
2.5 Single photon emission computed tomography, SPECT 
Nuclear medicine is the part of radiology in which a chemical or other substance contain-
ing a radioactive isotope is given to the patient somehow (orally, by injection or by inha-
lation). Once the material has distributed itself according to the physiological status of 
the patient, a radiation detector is used to make projection images from the x- or gamma 
rays emitted during radioactive decay of the agent. Nuclear medicine produces emission 
images, because the radioisotopes emit their energy from inside the patient [10]. 
SPECT-imaging is a form of nuclear imaging, which was invented in the early 
1960s [24]. SPECT is a tomographic imaging method that displays two-dimensional 
slices of the three-dimensional spatial distribution of injected radiopharmaceutical within 
the patient’s body. The radionuclide of the radiopharmaceutical emits gamma radiation 
that can pass through the body and gets detected by a gamma camera [25]. 
Gamma camera consists of collimator, detector crystal, photo-multiplier tubes and 
electronics. A block diagram of a gamma camera is presented in figure 2. Gamma radia-
tion emitted from the injected radiopharmaceutical interacts with the body, and gets al-
ready absorbed and scattered inside the body. The gamma radiation that radiates through 
the patient will first collide with the collimator. The collimator is a kind of a shield in 
front of the scintillation crystal that blocks out unwanted photons. The basic design of a 
collimator is a lead plate which contains a large amount of small holes. Only the photons 
that travel through the holes can cause scintillations in the crystal and participate on image 
formation.  Collimators differ by the hole diameter, hole length and the distance between 
hole centers. Different isotopes have different gamma energies and thus need different 
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type of collimators. Collimators are needed to find out the direction of the incoming ra-
diation. [26]. 
Gamma rays that find their way through the collimator hit the detector crystal. 
The crystal absorbs gamma photons and emits light in response. The crystal is usually 
made of sodium iodide, NaI(Tl). The thickness of the crystal is important. It should be 
thick to get good sensitivity. On the other hand, it cannot be too thick. The thicker the 
crystal, the greater the spread of the emitted light photons produced from the scintillation. 
The spread affects the computation of gamma ray interaction location resulting and the 
resolution of the gamma camera gets poorer [26]. 
 
 
Figure 2: A block diagram of a gamma camera. Modified from [28] 
 
Gamma photons interact with the scintillation crystal with two major methods: 
photoelectric absorption or Compton scattering. The photoelectric effect occurs when an 
incident gamma photon interacts with an inner-orbital electron and the entire energy of 
the gamma photon is transferred to the electron. The Compton Effect occurs when an 
incident gamma photon interacts with an outer-shell electron and transfers some of its 
energy to the electron, causing the electron to eject from its orbit. Due to the collision the 
energy and direction of the incident gamma photon changes. The scattered gamma photon 
may undergo further photoelectric absorption, or be re-scattered. With both methods, the 
electron raises to a higher energy level, and thus is in unstable state. As falling back to a 
lower energy level, the electron releases the extra energy as visible light [10]. 
The light emitted by the crystal is detected by photomultiplier tubes (PMTs). 
These tubes have two functions: convert the visible light into electrical signal and signal 
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amplification. The electrical signals are forwarded to preamplifiers that further amplify 
the signals, so as to minimize distortion and attenuation of the signal during transmission 
to the remainder of the system. After the preamplifiers the electrical signals is forwarded 
to the pulse height analyzer (PHA). The PHA is used to allow only pulses which corre-
spond to correct gamma energy to be accepted for image formation. Finally, the electrical 
signal is positioned by a computer.  
Gamma camera forms two-dimensional planar images, projections, where a single 
projection shows an in vivo distribution of the radiopharmaceutical within the body.  
SPECT requires that projection images are taken around the patient. These projections 
are reconstructed into a 3D image by reconstruction algorithms [25]. 
 
 
Figure 3: The basic principle of SPECT. The gamma camera rotates around the object, 
producing projections. The projections are combined to a sinogram, which is finally dig-
itally reconstructed by reconstruction algorithms to a 2D SPECT image. Modified from 
the [25]. 
 
There are two major methods to reconstruct SPECT images, either iteratively or 
by filtered backprojection technique [27]. The filtered backprojection method is the most 
widely used analytical reconstruction algorithm due to its speed, simplicity and compu-
tational efficiency. The algorithm includes two steps: filtration of data and back projec-
tion of the filtered data. The most used iterative reconstruction method is the maximum 
likelihood (ML) technique. The ML technique consists of 4 steps [27] (see also figure 4):  
1. Make an initial guess of the 3D image 
2. Calculate 2D projections of the current 3D  image estimate by forward projec-
tion 
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3.  Compare the forward-projected projections with the actual measured projec-
tions 
4. If calculated and measured projections do not match correct the 3D image and 
continue from 2.  
 
Figure 4: A diagram of the steps of the maximum likelihood technique. Modified from 
[43]. 
Modern gamma cameras are hybrid devices where gamma camera and CT scanner 
have been combined to form a SPECT/CT device. These devices have a lot of advantages. 
Of which the nearly perfect alignment of SPECT and CT images is probably the most 
important [10]. 
2.6 Dosimetry 
Dose calculation is important in ensuring the safety of the radionuclide treatments. The 
aim is to find a proper dose to treat the cancer without causing any harm to healthy tissue. 
Today, dosimetry is usually performed post-treatment. All the patients receive more or 
less the same treatment dose, but post-treatment dosimetry can be used to check does the 
patient tolerate a new treatment round in the future. Dosimetry could also be used pre-
treatment to tailor the treatment dose for each patient [10]. 
Dosimetry methods for radionuclide treatments can be roughly divided into the 
Medical Internal Radiation Dose (MIRD) based and voxel-based methods [10]. These are 
shortly described below.  
2.6.1 The Medical Internal Radiation Dose, MIRD 
MIRD is a mathematical tool for estimating the doses in nuclear medicine. The calcula-
tions are based on estimates or simplifying assumptions that provide approximation of 
the dose. The basic idea is that there are source organs and target organs. The source 
organ contains the radiation emitting substance, which the target organ absorbs. The mean 
dose to a target organ is calculated from the equation: 
 
 
𝐷(𝑟𝑇 , 𝑇𝐷) = ∑ ∫ 𝐴(𝑟𝑆, 𝑡)
1
𝑀(𝑟𝑇 , 𝑡)
∑ 𝐸𝑖𝑌𝑖𝜙(𝑟𝑇 ← 𝑟𝑆, 𝐸𝑖, 𝑡)
𝑖
𝑇𝐷
0𝑟𝑠
 (8) 
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where A(rS, t) is the activity for each source organ (rS) at time (t), M(rT, t) is the target 
organ mass at time t, Ei is the mean energy of a given radiation emission I, Yi is its yield 
(number emitted per nuclear transformation), and ϕ(rT ← rS, Ei, t) is the absorbed frac-
tion [10]. 
To ease the calculation, the MIRD committee has established S factors. The S 
factors are estimates of the absorbed doses of organs. These S factors have been calculated 
with the help of phantoms that represent average human anatomy and Monte Carlo meth-
ods. For example the pancreas being a target organ and the liver being a source organ for 
99mTc the S factor is 1.1 x 10-3 in mGy/MBq/hour. The S factor changes the equation (8) 
to form: 
 
 𝐷(𝑟𝑇 , 𝑇𝐷) = ∑ Ã(𝑟𝑆, 𝑇𝐷)𝑆
𝑟𝑆
(𝑟𝑇 ← 𝑟𝑆) (9) 
 
where Ã(rS, TD) is the time-integrated activity (i.e. the total number of disintegrations) in 
source organ during the specified dose integration period TD. According to equation (9) 
the only unknown quantity is the time-integrated activity in the source organs. This can 
be obtained by imaging the patient several times and extracting the time-activity curve 
from the images for each source organ. After the time activity curve has been extracted 
in can be easily integrated [10]. 
As the MIRD is based on assumptions, limitations and simplifications, there can 
be significant differences between the true and calculated doses. The main problems are:  
1. The radioactivity is assumed to be uniformly distributed in each organ. 
2. Each organ is assumed to be homogeneous in density and composition. 
3. Dose contributions from minor radiation sources are ignored. 
4. The organ sizes and shapes of each patient are different and might be very 
severly over- or underestimated by the MIRD organ sizes. 
5. There is no proper dose calculation model for tumors.  
Nevertheless, the MIRD is still the most commonly used dosimetry method due to its 
simplicity. It is primarily designed to be used in diagnostics and in radiation protection to 
allow direct comparison of radiation doses.  
2.6.2 Voxel-based dosimetry 
While the MIRD counts on average human-like phantoms, the voxel-based dosimetry 
uses different kind of approach to get the real anatomical and physical information about 
the sources and targets. Voxel-based dosimetry uses 3D dimensional SPECT or positron 
emission tomography (PET) images to estimate the amount of activity inside each voxel 
of the image and each imaging time point. These images are used as a starting point for 
point dose kernel or Monte Carlo calculations. In point dose kernel method a precalcu-
lated point dose kernel is used to convolve the time-wise integrated SPECT or PET image 
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to obtain an estimate of radiation dose in each image voxel. In Monte Carlo-based dose 
calculation a Monte Carlo simulator is used to track the particles and photons emitted 
from each source voxel and to calculate the dose to each target voxel. Both point dose 
kernel and Monte Carlo methods provide 3D patient specific maps of the dose in contrary 
to MIRD which only provides average doses per organ. 
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3 MATERIAL AND METHODS 
This chapter covers the introduction of applied materials, software, different segmenta-
tion methods and methods for evaluating the segmentation methods. The use of these 
methods and materials is demonstrated at the last two subchapters. 
3.1 Phantoms  
Phantoms are models used for simulations, and testing, analyzing, and tuning the perfor-
mance of imaging devices. Depending on the usage and the facilities, the phantom can be 
for example just a lead plate for testing or a complex anthropomorphic model for simula-
tions. Today, with the modern technology the phantom can be also fully programmed. A 
phantom is a safer and more cost-effective solution than the use of a real human object. 
It also provides more consistent results than the use of a living subject or a cadaver. The 
biggest advantage of using programmed phantoms is that they can be easily altered to 
model different anatomies and medical situations, providing a large population of subjects 
with which to perform research [10]. 
As the imaging techniques started to develop, so did the phantom technology. Not 
until the early 1960s, the first, very simple phantoms were used to measure radioactivity 
doses. The organs were assumed to be homogeneous areas inside the body and the source 
of the radiation was assumed to be located at the center of each organ [29]. 
The next step was a little more complex MIRD phantom that was developed by 
Fisher and Snyder in the late 1960s. The doses were based on the MIRD calculations, and 
the phantom itself was more abundant with several different organs. As mentioned above, 
the MIRD simplifies the doses, and its accuracy is questionable. With these old-fashioned 
and so called stylized phantoms, the representation of organs is simplistic, by capturing 
only the most general description of the position and geometry of each organ, and thus 
they gave just rough estimates of the doses [29, 30]. 
As the imaging technology continued developing, the 3D imaging techniques such 
as magnetic resonance imaging (MRI) and computed tomography (CT) became popular. 
Hence, the new generation of 3D voxel-based phantoms was developed in the 1980s. 
Unlike before, the dose could be calculated based on diagnostic data, thus being more 
accurate than the rough estimates. Soon after this, the next step was the invention of a 4D 
phantom [30]. 
The first model of the new phantom generation was a 4D mathematical cardiac 
torso (MCAT) phantom. It was still based on the MIRD computational phantom, but was 
anatomically more accurate and realistic than the old MIRD version. Due to its geomet-
rical design, the MCAT phantom suffered from the lack of ability to realistically model 
the human anatomy [29]. 
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The next phantom model was based on imaging data, which made it much more 
realistic than the MCAT phantom. The non-uniform rational B-spline (NURBS) -based 
cardiac torso (NCAT) phantom is also used in this thesis. The NCAT phantom was orig-
inally developed for low-resolution nuclear medicine imaging research, and for that rea-
son it includes only a limited number of structures restricted to the region of the torso. 
Despite or because of it, this phantom model is suitable for this thesis [29, 30]. 
The NURBS is a mathematical modeling tool that is widely used in computer 
designing, and it is very useful also with phantoms. The advantages of this method is that 
it can accurately represent both standard geometric objects like lines, circles and spheres, 
and free-form geometry like human bodies. Also, it can be evaluated relatively fast by 
numerically stable and accurate algorithms. The shape and volume of a NURBS -based 
phantom can be adjusted with coordinates of control points. This feature is useful in de-
signing a time-dependent 4D human body modeling [29]. 
The phantom technology has gone even further and one of the newest versions is 
an extended cardiac torso (XCAT) phantom. The XCAT phantom is an updated version 
of the NCAT phantom. The anatomy and physiology is even more detailed, and the 
XCAT phantom is rather used with higher-resolution imaging applications such as MRI 
or CT. The accuracy of the XCAT phantom is based on the combination of NURBS and 
subdivision (SD) surfaces. The Subdivision surfaces are capable of modeling smooth 
structures with an arbitrary topological type, such as the structures in the brain. These 
kinds of structures are hard and almost impossible to model with the NURBS [29]. The 
different phantom models are presented in figure 5. 
 
 
Figure 5: Different phantom models. Modified from [29]. 
 
The used phantom software can scale the phantom in many different ways 
(weight, height, volume), and the activities of the organs can be adjusted as wanted. The 
software is also able to take into account the respiratory and cardiac motions of the object. 
The phantoms (6 phantoms in total) used in this study were made with default 
settings, only activity distributions of the organs were pre-set. The activity distributions 
of the organs were constructed based on 10 randomly selected anonymous patients going 
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through 177Lu-treatment. The activity distributions were defined in two different time 
points: 24 hours and 168 hours after the treatment. The phantoms were created in 
128x128x128-matrix size and 4.8 mm pixel size. 
Lesions were included to the phantom with Matlab R2014a (The MathWorks, 
Inc., Natick, Massachusetts, USA), thus in practical terms the phantom is a modified 
NCAT phantom. The tumor sizes were 11ml, 16ml and 90ml for 24 hours, and 5ml, 15ml 
and 90ml for 168 hours. The idea was to have small, medium and large tumors in both 
groups. 
 After the activity and attenuation maps of the phantom had been determined, the 
activity projections were simulated using a Monte Carlo simulator [31]. Parameters were 
chosen to match the widely used Siemens Symbia SPECT/CT system. The attenuation of 
the radiation, the scattering in the phantom and camera characteristics were taken into 
account during the simulation. Images from different steps of the phantom data recon-
struction process are presented in figure 6.  
 
 
Figure 6: On the left is a coronal slice from the real phantom data. The second image 
from the left includes a simulated projection. The third image from the left is a sinogram 
from a certain height. On the right image is a coronal slice from the reconstructed phan-
tom data.  
 
HydridRecon reconstruction software (HERMES Medical Solutions, Stockholm, 
Sweden) was used to reconstruct the final slices from the projections. The used recon-
struction algorithm is the ordered-subset expectation-maximization (OS-EM) algorithm. 
The OS-EM method is an iterative method used for mathematical optimization, and is a 
popular reconstruction algorithm due to its speed [32]. 
3.2 Segmentation methods 
Image segmentation is a process, where an image is divided into multiple segments. The 
goal is to highlight relevant parts of the image and further improve the conditions of im-
age analysis.  Tumor dosimetry partly relies on the segmentation of the tumors from the 
background organs. The segmentation of the tumors is necessary to get the tumor ab-
sorbed dose. This segmentation can be done manually, but that is time consuming, sub-
jective, error prone and not reproducible. Automatic segmentation methods on the other 
hand are fast, objective and often 100% reproducible [5]. 
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Four different segmentation methods are first introduced, and then used and com-
pared in this thesis. These segmentation methods are thresholding, k-means clustering, 
fuzzy-c-means clustering and expectation maximization. These methods were used to 
segment tumors from the SPECT images mentioned above. 
3.2.1 Thresholding 
Thresholding is one of the simplest, yet one of the most important and used image seg-
mentation methods. Thresholding has several modifications, but the basic function is al-
ways more or less the same. Each voxel has its own intensity value f(x,y). The threshold 
value T can be chosen by the user by trial and error or with for example the help of inten-
sity histogram of the image. When T is set, the intensity value of a voxel is compared 
with the threshold value T and as a result each voxel gets a new value g(x,y) as below: 
 
 
𝑔(𝑥, 𝑦) = {
𝑓(𝑥, 𝑦) ≥ 𝑇 = 1
𝑓(𝑥, 𝑦) < 𝑇 = 0
 (10) 
 
A gray-scale image turns into a binary image. By changing the threshold value T, the 
balance of the image changes [33]. 
3.2.2 K-means clustering 
Clustering includes a group of segmentation methods that classify objects or patterns in 
such a way that samples of the same group are more similar to one another than samples 
belonging to different groups. A clustering method tries to find a structure in a collection 
of unlabeled data. 
The k-means (KM) clustering is a widely used segmentation method due to its 
simplicity. It is a method that divides an image into k different clusters and each k cluster 
has a centroid. The centroids are selected either manually or randomly. After the positions 
of the centroids have been selected, each pixel of the image is associated to the nearest 
centroid [5]. 
The second step is to calculate k new centroids as barycenters of the clusters re-
sulting the previous step. Because of the new centroids, the pixels have to be re-associated 
with these new centroids [5]. 
After the pixels are re-associated, the balances of the clusters are changed again. 
The third step is to re-calculate the barycenters, and continue re-calculations step by step 
until the loop has found the best possible positions of the centroids. As a result the algo-
rithm tries to minimize the following objective function: 
 
 
𝐽(𝑥, 𝑐) = ∑,
𝑁
𝑖=1
∑ ||𝑥𝑖 − 𝑐𝑘||
2
𝐾
𝑘=1
 (11) 
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where N is the number of voxels, K is the number of tissue classes, xi is a feature vector 
at the ith location and c is the kth class cluster center [5]. 
Noteworthy is that the k-means algorithm does not necessarily find the most op-
timal configuration, but the best result possible with the given k value. Unfortunately, 
there is no general theoretical solution to find the optimal number of clusters for any given 
data set. One solution is to run the algorithm several times with several different k values, 
and compare the results.  
The KM has few disadvantages. The biggest is that each pixel can belong only to 
one cluster. Also, this technique is not robust to noise and spatial inhomogeneity.  
3.2.3 Fuzzy-c-means clustering 
Fuzzy-C-means (FCM, also known as fuzzy k-means) clustering is a method that tries to 
avoid problems that occur with k-means clustering. The FCM is developed by Dunn in 
the early 1970’s [34] and the method is improved by Bezdek et al. in 1982 [35]. The idea 
is to enable a voxel to belong to more than one cluster. The algorithm works similarly to 
k-means algorithm, but the cluster association is done by using fuzzy membership func-
tions developed by Zadeh [36]. 
The fuzzy membership function represents the amount of stochastic overlapping 
between the tumor region and surrounding regions. In the FCM case, the fuzzy member 
function at any iteration n is given by: 
 
 
𝑢𝑖𝑘
(𝑛)
=
||𝑥𝑖 − 𝑐𝑘
(𝑛)
||−2
∑ ||𝑥𝑖 −
𝐾
𝑘=1 𝑐𝑘
(𝑛)
||−2
 (12) 
   
and the update for cluster centers is: 
 
 
𝑐𝑘
(𝑛+1)
=
∑ (𝑢𝑖𝑘
(𝑛)
)𝑏𝑥𝑖
𝑁
𝑖=1
∑ (𝑢𝑖𝑘
(𝑛)
)𝑏
𝑁
𝑖=1
 (13) 
 
where 𝑥𝑖 again is the feature vector at the ith location, 𝑐𝑘
(𝑛)
 is the kth centroid at the nth 
iteration and b is an exponent > 1 [5]. 
The algorithm follows the same steps as the k-means algorithm. First, the number 
of clusters have to be defined. After that, the cluster centers are updated until the algo-
rithm finds the best position for the centroids [5]. 
The FCM is a popular segmentation method due to its robust characteristics for 
ambiguity. Also, it retains much more information than for example k-means clustering. 
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Nevertheless, it does not include any information about spatial context, which makes it 
sensitive to noise and imaging artefacts [5]. 
3.2.4 Expectation maximization 
Expectation maximization (EM) is a stochastic modelling method that tries to exploit the 
statistical differences in intensity distribution between tumor and its tissue surroundings. 
The EM algorithm is a general approach for maximum likelihood estimation [5]. 
The theory behind the segmentation method is presented by Dempster et al. [37]. 
Each iteration of the EM algorithm involves two steps, which are called the expectation 
step (E-step) and the maximization step (M-step). The E-step is for computation of the 
probabilities and the M-step estimates the cluster parameters assuming that the intensity 
distribution of each class may not be Gaussian and assigns belonging probabilities ac-
cording to non-Gaussian distributions [5]. 
The approach used in this thesis is presented by Zaidi & El Naga [5]. Zaidi & El 
Naga assume that the image intensities are independent and identically distributed with a 
Gaussian probability density function that could be divided into three regions: back-
ground, the uncertain and the target regions. The likelihood function is written as: 
 
 
𝐿(𝜋, µ, 𝜎) = ∏ 𝑓(𝑥𝑖 𝜋, µ, 𝜎) = ∏,
𝑁
𝑖=1
∑
𝜋𝑘
√2𝜋𝜎𝑘
2
𝐾
𝑘=1
⁄
𝑁
𝑖=1
𝑒
−
(𝑥𝑖−µ𝑘)
2
2𝜎𝑘
2
 (14) 
 
Where N is the number of voxels, K is the number of classes, 𝜋 are the mixing parameters 
and µ, 𝜎 are the Gaussian parameters. The maximum likelihood estimates of the unknown 
parameters are obtained using the EM algorithm and the probability of voxel xi belonging 
to class k is given by: 
 
 
𝑝𝑖𝑘 =
𝑥𝑘𝑓𝑘(𝑥𝑖 µ𝑘, 𝜎𝑘)⁄
∑ 𝜋𝑚𝑓𝑚
𝐾
𝑚=1 (𝑥𝑖 µ𝑚, 𝜎𝑚)⁄
 (15) 
 
The results derived using these methods will be denoted from here onwards as TH 
XX (XX depending on the used threshold value), KM, FCM and EM.  
There is a connection between the clustering methods (FCM and KM) and the 
EM. The KM and the FCM could be defined as variations of the expectation maximiza-
tion algorithm. Both methods even include the E- and M-steps, to be precise. In fact, the 
KM is also called the hard EM method in the literature, while the EM is called the soft 
EM method. It is a little confusing, because at the same time the FCM is called the soft 
version of KM, but still it is not the same thing than the soft EM method [38]. 
The terms hard and soft refer to the methods used for dividing the data to clusters. 
The KM divides the data to clusters as one data point belonging to only one cluster. This 
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is the hard method. The FCM and the EM are softer methods, allowing the data points to 
belong to several clusters [38]. 
The biggest difference between the clustering methods and the EM is the model 
of the cluster. The clustering methods model their clusters as spheres in n-dimensional 
space, and the EM models its clusters as probability density functions, which can have 
also elliptical shapes. Thus, the criterions of the segmentation are different. With cluster-
ing methods the data is clustered by the distance to a centroid, whereas the criterion for 
the EM-algorithm is the probability of a data point given the probability density function 
of the cluster center [38]. 
3.3 Comparison of the segmentation methods 
The functionality of the segmentation methods can be seen from the images visually, but 
the comparison only made based on the sense of sight is subjective, and is not accurate 
enough or even scientifically relevant. 
To get some concrete results from the data, there has to be some known compari-
son algorithms to use. We have three different comparison methods. Two of them, Dice 
similarity coefficient and Classification error are used with the phantom data. The third 
method, the integral of the time activity curve is used with the patient data, which was 
used in addition to phantom data. The patient data is described in section 3.5 in more 
detail. 
3.3.1 Dice similarity coefficient 
Dice similarity coefficient (DSC) is a spatial overlap index. It measures the similarity of 
two different data sets A and B. The DSC calculates the intersection of the two data sets, 
multiplies it by two, and divides the result with the total area of the data sets. The DSC is 
calculated with the given formula: 
 
 
𝐷𝑆𝐶 =
2(𝐴 ∩ 𝐵)
(𝐴 + 𝐵)
 (16) 
 
Intersection formally: 𝐴 ∩ 𝐵 = {𝑥 ∶ 𝑥 ∊ 𝐴 ∧ 𝑥 ∊ 𝐵}. The intersection is a data set that 
contains all elements of A that also belong to B, and vice versa, but no other elements. 
[39] 
The DSC values range from 0, indicating no spatial overlap between two sets of 
binary segmentation results, to 1 indicating complete overlap. So, the closer the value is 
to 1, the better the result [39]. 
3.3.2 Classification error 
The Classification error (CE) tries to find the failures the segmentation method does while 
segmenting the tumor from the SPECT image. It is possible that the segmentation method 
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classifies the data wrong either positively or negatively. The positive classification error 
means that the voxel is classified falsely to the sphere (lesion) and the negative classifi-
cation error means that the voxel is classified falsely to the background. The CE is calcu-
lated with the formula: 
 
 
𝐶𝐸 =
(𝑃𝐶𝐸 + 𝑁𝐶𝐸)
𝑉𝑜𝑆
 × 100% (17) 
 
where PCE is the positive classification error, NCE is the negative classification error and 
VoS is the number of voxels defining the sphere [40, 41]. 
The closer the CE value is to 0%, the smaller and the better is the result of the 
classification error. If there is a large number of misclassified voxels, the size of classifi-
cation error might get even bigger than 100%. In the literature the CE value is usually 
limited to 100% or 200%, since any bigger values represent complete failure of the seg-
mentation process. In this thesis, the CE value is unlimited, because the aim is to find the 
differences between the segmentation methods, no matter how large the CE values are 
[40, 41]. 
3.3.3 Integral of the time activity curve 
Tumor time activity curve can be generated by plotting imaging time point versus the 
number of total counts extracted from the SPECT images of the tumor. The integral of 
this curve is directly proportional to the number of decays that happen inside the tumor 
and therefore also directly proportional to the tumor absorbed dose, because in 177Lu-
treatments the locally absorbed electrons nearly create the entire dose.  
 The time activity curve integral was calculated by first fitting single exponential 
function to the raw time activity curve and then analytically integrating the exponential 
fitting curve from 0 to infinity. The result value is called Area under the curve (AUC). 
3.4  Segmentation with the phantom data 
In this part, the mathematical phantoms described in section 3.1 are under research. The 
lesions are segmented with four segmentation methods introduced earlier: thresholding, 
k-means, fuzzy-c-means and expectation maximization. Segmentation was performed us-
ing an in-house developed program ROITest.  ROITest calculates the volume of the le-
sion, the total number of counts, and a ROI (region of interest) -mask. The software is 
programmed so that the ROI-mask data includes only the voxels of the segmented lesion. 
To get information about the functionality of the segmentation method, the resulting ROI-
mask is compared with the ground truth data (i.e. the tumors extracted from the developed 
phantoms). At the end of the segmentation session, there are 24 different ROI-masks to 
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be studied and compared. The comparison with the ground truth is performed with meth-
ods introduced earlier: dice similarity coefficient and classification error. A flowchart of 
the phases of the work is presented in figure 7. 
  
 
Figure 7: A flowchart of the steps of the work with the phantom data. 
 
ROITest resamples the 128x128x128 sized phantom data and opens it as a three-
dimensional, sized 256x256x256, matrix, where each layer presents a two-dimensional 
SPECT image. The matrix can be scrolled layer by layer as a SPECT image by a SPECT 
image. ROITest shows the data in three different planes: transversal, coronal and sagittal. 
The segmentation is implemented with the transversal images, the other two planes are 
just for assistance. When segmenting the lesion, the first step was to find the center of the 
lesion from the slices. The second step was to decide an appropriate box size, inside which 
the whole lesion fitted. The box size is given in centimeters. The box was used to guide 
the segmentation method to work on the tumor area. 
The next step was to choose the wanted segmentation method and finally the soft-
ware calculated the results. As a result the software generated the volume of the lesion, 
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the count number of the lesion, and a ROI-mask. The ROI-mask was then saved for fur-
ther studies. ROITest also generates the average of the number of the counts, but it is not 
used in this thesis. ROITest is presented as a screenshot in figure 8. 
 
 
Figure 8: A screenshot of ROITest. The lesiontumor is segmented from the transversal 
image. The sagittal and coronal images on the left are just for assistance.  
 
The ROI-mask was compared with the phantom data in Matlab. The used Matlab 
code is introduced in Appendix A. The formula (16) was used for calculating the DSC, 
and the formula (17) was used for calculating the CE. In DSC case, A is the ROI-mask 
and B is the phantom data. The comparison is first made two-dimensionally slice by slice. 
After that, the two-dimensional results are summed, and finally the result is a three-di-
mensional matrix, whereof Matlab calculates the DSC value of the whole mask. The CE 
comparison was made similarly first slice by slice, and finally the result comes from 3-D 
matrix. 
3.5 Segmentation with the patient data 
In this part, the same segmentation methods used with phantom data are used with real 
patient data. Because the real size of the lesion is unknown, there is no ground truth data 
available. Thus, the DSC and the CE are useless, and the integral of the time activity curve 
is the only comparison method used with the patient data. The lack of the ground truth 
data also means that the results are only estimates. The only important parameters that 
ROITest calculates are count numbers of the lesions.   
The patient SPECT data was collected after three different 177Lu-dotatate treat-
ments. The patient was SPECT imaged after each treatment. After the first treatment the 
patient was imaged after 1 hour, and after 24, 48 and 168 hours. After the latter two treat-
ments, the patient was imaged after 24, 48 and 168 hours. Hence, there is data from ten 
27 
 
different imaging sessions. The patient SPECT data was also reconstructed with Hy-
bridRecon. The data had several tumors, but we decided to choose just one lesion for 
testing the segmentation methods. The steps of the patient data segmentation have been 
presented in the flowchart in figure 9. 
 
Image 9: A flowchart of the steps of the work with the phantom data.  
 
The segmentation was again made with ROITest, and in the same way as with the 
phantom data. Unlike with the phantom data, there is no need for saving the ROI-masks. 
Just the volumes and counts are taken up. As the lesion is segmented the ROITest tells 
the volume and the number of counts in the segmented region. An example of the results 
ROITest calculated is presented in figure 10. 
 
 
Figure 10: An example of results given by ROITest. ROITest generates the volume of 
the lesion, the total count number of the lesion and the average of the number of the 
counts. 
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The calculations and graphs have been made with Microsoft Excel 2013 (Microsoft Cor-
poration, Redmond, Washington, USA). The counts calculated for each data set are com-
bined to graphs. Every treatment has its own graph. The counts at different time points 
form a curve. With the help of Excel, the exponential trend line can be drawn. The value 
of the AUC is the integral of the formula of the trend line. 
 After the results were ready, it became clear that the results of the imaging one 
hour after the first injection were irrelevant considering the integral calculations. The 
trend line could have been hard to fit if the imaging data had been included to the graph. 
However, the data is available in the table 2. It clearly shows that the amount of the radi-
opharmaceutical is not yet at the maximum on the target area, one hour after the injection. 
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4 RESULTS 
Following the procedures described in the material and methods chapter, the results of 
this thesis are divided into two categories: the results obtained with segmenting the phan-
tom data and the results obtained with segmenting the patient data.   
4.1 Results with the segmented phantom data 
Matlab calculation of the DSC and CE values took about 36 to 38 seconds per ROI-mask. 
The volumes are calculated with ROITest, and their accuracy with a calculator. The re-
sults are presented in table 1. The results are listed to the table phantom by phantom. The 
first three are the phantoms imaged 24 hours after the treatment and the latter three are 
the phantoms imaged 168 hours after the treatment.  
The segmentation methods are listed in relation to their accuracy, starting from 
the weakest accuracy. However, the last two segmentation methods listed are the thresh-
olding values. The first one is the reference value (TH20), and the second one is the op-
timal value. The optimal TH values were determined by trial and error. The reference 
value was decided after the calculations. 
The figures 11-16 are presented in the same order as the segmentation methods 
are in table 1 with the difference that the results with the reference value of the TH (TH20) 
are not imaged, but only the optimal TH values. The images are divided into six groups 
of four images, just like the results in the table. In the images from left to right there is 
the ground truth, the ROI-mask, the result with the DSC and the result with the CE. The 
segmentation is made three-dimensionally, but the images are pieces of the center slices 
of the ROIs. The three-dimensional images from the whole matrices could have been 
visually more aesthetic, but the needed information can be clearly seen also with the im-
ages introduced below. Furthermore, the chosen imaging style is widely used in the re-
search literature. 
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Table 1: The results with the phantom data. On the first column on the left, there is in-
formation about the used phantoms. The second column from the left presents the used 
segmentation methods. The methods are K-means clustering (KM), Fuzzy-C-means clus-
tering (FCM), Expectation maximization (EM) and Thresholding (TH) with a reference 
value and a modified value. The third column from the left presents the volumes calcu-
lated with ROITest in milliliters. The fourth column presents the accuracy of the calcu-
lated volume in relation to the real tumor volume presented on the first column on the 
left. The last two colums present the results with Dice similarity coefficient (DSC) and 
Classification error (CE). 
Phantom data 
Segmentation 
method 
Tumor volume 
(ROITest) [ml] 
Tumor volume 
accuracy [%] DSC CE [%] 
Phantom 1 KM 7.20 64 0.73 44 
Tumor volume: 11.2ml FCM 7.30 65 0.73 43 
Time from injection: 24h EM 10.2 91 0.83 31 
  TH 20 9.20 83 0.80 34 
  TH 17 10.9 98 0.84 31 
Phantom 2 KM 8.00 49 0.66 51 
Tumor volume: 16.1ml FCM 8.20 51 0.67 50 
Time from injection: 24h EM 13.6 84 0.84 29 
  TH 20 10.8 67 0.78 36 
  TH 14 15.7 97 0.86 28 
Phantom 3 KM 73.5 81 0.89 21 
Tumor volume: 90.2ml FCM 72.5 80 0.88 21 
Time from injection: 24h EM 83.2 92 0.92 15 
  TH 20 103.8 85 0.91 19 
  TH 26 89.9 100 0.93 14 
Phantom 4 KM 3.10 61 0.70 48 
Tumor volume: 5.0ml FCM 3.20 63 0.71 47 
Time from injection: 168h EM 5.10 97 0.78 44 
  TH 20 4.00 79 0.75 43 
  TH 15 5.20 96 0.78 43 
Phantom 5 KM 7.70 53 0.67 50 
Tumor volume: 14.5ml FCM 7.70 53 0.67 50 
Time from injection: 168h EM 15.7 92 0.85 30 
  TH 20 9.9 68 0.77 39 
  TH 13 14.9 97 0.85 29 
Phantom 6 KM 72.7 81 0.88 22 
Tumor volume: 89.6ml FCM 72.0 80 0.88 22 
Time from injection: 168h EM 87.2 97 0.93 14 
  TH 20 97.8 91 0.93 15 
  TH 24 89.8 100 0.93 14 
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The results with the imaging data of the phantom 1 with an 11ml tumor, 24 hours after 
the treatment are calculated with the box size of 4cm x 4cm x 4cm. The results are pre-
sented in figure 11. 
 
 
 
 
 
Figure 11: The result images with the imaging data of a phantom with an 11ml lesion, 
24 hours after the treatment. The upper row is the results with the KM, the second row 
is the results with the FCM, the third row is the results with the EM and at the bottom 
row is the results with the optimal TH value (TH 17). The spheres are from left to right 
the ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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The results with the imaging data of the phantom 2 with a 16ml lesion, 24 hours after 
the treatment are calculated with the box size of 5cm x 5cm x 5cm. The results are pre-
sented in figure 12. 
 
 
 
 
 
Figure 12: The result images with the imaging data of a phantom with a 16ml lesion, 24 
hours after the treatment. The upper row is the results with the KM, the second row is 
the results with the FCM, the third row is the results with the EM and at the bottom row 
is the results with the optimal TH value (TH 14). The spheres are from left to right the 
ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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The results with the imaging data of the phantom 3 with a 90ml lesion, 24 hours after 
the treatment are calculated with the box size of 7cm x 7cm x 7cm. The results are pre-
sented in figure 13. 
 
 
 
 
 
Figure 13: The result images with the imaging data of a phantom with a 90ml lesion, 24 
hours after the treatment. The upper row is the results with the KM, the second row is 
the results with the FCM, the third row is the results with the EM and at the bottom row 
is the results with the optimal TH value (TH 26). The spheres are from left to right the 
ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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The results with the imaging data of the phantom 4 with a 5ml lesion, 168 hours after 
the treatment are calculated with the box size of 4cm x 4cm x 4cm. The results are pre-
sented in figure 14. 
 
 
 
 
 
Figure 14: The result images with the imaging data of a phantom with a 5ml lesion, 168 
hours after the treatment. The upper row is the results with the KM, the second row is 
the results with the FCM, the third row is the results with the EM and at the bottom row 
is the results with the optimal TH value (TH 15). The spheres are from left to right the 
ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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The results with the imaging data of the phantom 5 with a 15ml lesion, 168 hours after 
the treatment are calculated with the box size of 5cm x 5cm x 5cm. The results are pre-
sented in figure 15. 
 
 
 
 
 
Figure 15: The result images with the imaging data of a phantom with a 15ml lesion, 
168 hours after the treatment. The upper row is the results with the KM, the second row 
is the results with the FCM, the third row is the results with the EM and at the bottom 
row is the results with the optimal TH value (TH 13). The spheres are from left to right 
the ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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The results with the imaging data of the phantom 6 with a 15ml lesion, 168 hours after 
the treatment are calculated with the box size of 7cm x 7cm x 7cm. The results are pre-
sented in figure 16. 
 
 
 
 
 
Figure 16: The result images with the imaging data of a phantom with a 90ml lesion, 
168 hours after the treatment. The upper row is the results with the KM, the second row 
is the results with the FCM, the third row is the results with the EM and at the bottom 
row is the results with the optimal TH value (TH 24). The spheres are from left to right 
the ground truth, the ROI-mask, the result with the DSC and the result with the CE. 
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4.2 Results with the segmented patient data 
The results are divided into three groups according to the number of the treatment. Tables 
2-4 show the counts of the calculated lesion per each segmentation method per hours after 
the treatment. Graphs 1-3 show the same results visually. 
The integral values are calculated from the curves by taking the exponential trend 
line of each curve and integrating them from 0 to infinity. After the integrals have been 
calculated the integral of different segmentation methods are scaled. The scaling is done 
by comparing the results to the highest integral value, the highest being 100%.   
4.2.1 The first treatment 
Table 2 and graph 1 include the results of the imaging period after the first treatment. 
Noteworthy is that table 1 includes also the count data of the imaging made one hour after 
the treatment. It is irrelevant information considering the AUC calculation, but it is pre-
sented here as a reference to the increasing of the counts in the target area. After a certain 
point the number of counts starts to decrease. The integral of the exponential fitting curve 
does not take into account the fact that the number of counts at time zero starts from zero, 
but it fits itself to the descending curve. Thus, the result is distorted. 
 
Table 2: Results with the patient data after the first injection. On the left is the time after 
the treatment in hours. On the right are the counts calculated with the different segmen-
tation methods. The factor of each count number is 106. 
 Counts per segmentation method [106] 
Time [hours] EM FCM KM TH 13 
1 2.2 2.1 2.1 3.2 
24 3.5 2.6 2.6 3.4 
48 2.8 2.0 2.0 2.6 
168 1.5 1.2 1.2 1.5 
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Graph 1: The results from the first treatment. The number of counts presented as a 
function of time. 
 
The integrals have been calculated from the curves and the results are: 
𝐴𝑈𝐶𝐸𝑀 = ∫ 4 × 10
6
∞
0
𝑒−0.006𝑥𝑑𝑥 = 6.67 × 108 
𝐴𝑈𝐶𝐹𝐶𝑀 / 𝐾𝑀 = ∫ 3 × 10
6𝑒−0.005𝑥𝑑𝑥 = 6 × 108
∞
0
 
𝐴𝑈𝐶𝑇𝐻 = ∫ 4 × 10
6𝑒−0.005𝑥𝑑𝑥 = 8 × 108
∞
0
 
FCM and KM has a similar curve, thus the integral is the same. AUCTH has the biggest 
value. After scaling, the results are: 
𝐴𝑈𝐶𝑇𝐻 = 100%
 
𝐴𝑈𝐶𝐸𝑀 = 83%
 
𝐴𝑈𝐶𝐹𝐶𝑀 / 𝐾𝑀 = 75%  
4.2.2 The second treatment 
Table 3 and graph 2 include the results of the imaging period after the second treatment. 
This time, the patient is imaged only three times after the treatment.  
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Table 3: Results with the data after the second treatment. On the left is the time after the 
treatment in hours. On the right are the counts calculated with the different segmentation 
methods. The factor of each count number is 106. 
  Counts per segmentation method [106] 
Time [hours] EM FCM KM TH 10 
24 3.95 3.00 3.00 4.05 
48 2.85 2.10 2.10 2.50 
168 1.55 1.10 1.15 1.45 
  
 
 
Graph 2: The results from the second injection. The number of counts presented as a 
function of time. 
 
The equations of the curves are integrated, and the results are presented below: 
𝐴𝑈𝐶𝐸𝑀 / 𝑇𝐻 = ∫ 4 × 10
6𝑒−0.006𝑥𝑑𝑥 = 6.67 × 108
∞
0
 
𝐴𝑈𝐶𝐾𝑀 / 𝐹𝐶𝑀 = ∫ 3 × 10
6𝑒−0.006𝑥𝑑𝑥 = 5 × 108
∞
0
 
The results after scaling are presented below: 
𝐴𝑈𝐶𝐸𝑀 / 𝑇𝐻 = 100%
 
𝐴𝑈𝐶𝐾𝑀 / 𝐹𝐶𝑀 = 75%
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4.2.3 The third treatment 
Table 4 and graph 3 include the results of the imaging period after the third treatment. 
Noteworthy is, that the used TH value is different than the one used with the other two 
treatment times. This is due to the problem that with the value 10 the TH took lots of 
surrounding tissue or organs within, and the number of the counts was clearly miscalcu-
lated. TH 13 was the lowest value that could perform the segmentation without taking 
surrounding tissue within.  
 
Table 4: Results with the data after third treatment. On the left is the time after the 
treatment in hours. On the right are the counts calculated with the different segmenta-
tion methods. The factor of each count number is 106. 
 Counts per segmentation method [106] 
Time [hours] EM FCM KM TH 13 
24 2.50 2.00 2.00 2.40 
48 1.90 1.40 1.40 1.90 
168 1.55 1.15 1.15 1.50 
   
 
Graph 3: The results from the third injection. The number of counts presented as a func-
tion of time. 
 
The integral of each segmentation method is similar: 
𝐴𝑈𝐶𝐸𝑀 / 𝐾𝑀 / 𝐹𝐶𝑀 / 𝑇𝐻 = ∫ 2 × 10
6𝑒−0.003𝑥𝑑𝑥 = 6.67 × 108
∞
0
 
Thus, the result after scaling is: 
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𝐴𝑈𝐶𝐸𝑀 / 𝐾𝑀 / 𝐹𝐶𝑀 / 𝑇𝐻 = 100%. 
Noteworthy is that, as it is shown in graph 3, looks like the resulting areas would not be 
similar. If the areas were calculated with given points of time (24, 48,168), the areas 
would not match. The final result differs from the graph due to the integral of the expo-
nential fitting curve. The integral is just an approximation of the real number of all counts 
from 0 to infinity. There is also a great variance between the activities. Thus, the curve 
fittings are hard to hit correctly. 
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5 DISCUSSION 
The goal of this thesis was to evaluate four lesion segmentation methods (thresholding, 
K-means clustering, Fuzzy-C-means clustering and Expectation maximization) used in 
PRRT with Dice similarity coefficient, Classification error and integral of the time activ-
ity curve. The results from performed studies are interpreted in this chapter. Furthermore, 
the own working during the project is evaluated. 
 According to the phantom data results, the EM seems to be the most accurate and 
most reliable segmentation method of the four evaluated methods. With almost every 
phantom, the EM calculates the volume of the lesion with the accuracy of at least 90 
percent. 
Also, the results with the modified TH values are accurate, but the most optimal 
value changes between the volumes of the lesions and the imaging times. The results with 
the reference value TH20 have a great variance between different data sets. 
Calculating the most optimal thresholding value with ROITest took time, because 
it had to be sought. In the literature, for PET images the optimal value for TH is between 
40 and 50 [5, 39]. It was claimed that the TH value of 42 would be the most optimal [39, 
40]. The search for the optimal TH value for SPECT images was started with those TH 
values presented in the literature. It was soon realized, that because the SPECT image has 
worse resolution than PET, the TH value has to be much lower. This research states that 
the optimal TH values are highly depended on the size of the lesion. With larger lesions 
it would be approximately 25 and with smaller about 15. As the lesion gets larger, also 
the TH value gets bigger. Noteworthy is, that as the TH value being the not-optimal ref-
erence value, the results still were always more accurate than with the FCM and the KM. 
It should also be noted that in real clinical situations optimal TH value is of course un-
known. 
The weakest segmentation methods are the FCM and the KM. The results with 
these segmentation methods are almost similar. When comparing the results, the differ-
ence between these two is really just cosmetic. The theory might give such an illusion 
that the FCM is a more accurate method than the KM. But when these two converge, with 
both segmentation methods, all the data points will be hard-assigned to a particular clus-
ter, if the probability of it in that cluster is the highest. This denotes that the results are 
very close to each other. 
The results are relatively more accurate with bigger (90 ml) lesions. Although, the 
amount of voxels is also larger, which could explain the effect. On the other hand, the 
results with smallest lesions (5 ml and 11 ml) are more accurate than with the medium-
sized (14 ml and 16 ml) lesions. 
The results are consistent and no major dispersions can be seen. Although, the 
results with ROITest are slightly better than the results with Matlab. For example, there 
are cases where the volume calculated with ROITest seems to be perfectly accurate, but 
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the DSC and the CE shows that there are some mismatched voxels. This tells us that the 
volume calculation is often not a good metric when segmentation methods are evaluated.  
All the segmentation methods were sensitive to the bounding box, which is used 
to guide the segmentation to the tumor area, location and size. It is important to adjust it 
properly. If it is adjusted too large, the software includes extra material and the volume 
increases falsely large, and if it is too small, some parts of the tumor may stay outside the 
calculation. 
The accuracy of the patient data results is hard to define because there is no ground 
truth. The results with integrating the exponential fitting curve are just rough estimates. 
Thus, it is not the optimal solution for evaluating the accuracy of the segmentation meth-
ods. Nevertheless, the results with the patient data are similar to the results with the phan-
tom data. The results with the EM and the TH visually differ clearly from the results with 
the KM and the FCM. The patient data results also show that segmentation can have a 
relatively big impact on the tumor dose. 
In the literature, the manual segmentation is referred to be the most accurate and 
widely used segmentation method there is available. It is also stated to be a time-consum-
ing and subjective method. [5] Manual segmentation was not tested here because it re-
quires an experienced expert to do the segmentation.  
Evaluation of the own work 
This work was made in co-operation with Eero Hippeläinen and Antti Sohlberg, because 
it is a part of Hippeläinen’s doctoral thesis. The phantoms were generated, simulated, 
reconstructed and segmented by methods developed by Hippeläinen and Sohlberg.  
My part of the work was to test the segmentation methods. I ran all the segmenta-
tion experiments and wrote the Matlab codes to analyze the results. I also wrote the thesis. 
There were few mistakes. Some minor, some little bigger. The most important thing is 
that during the practical part I was able to find my own mistakes by myself. 
The generation of the Matlab codes was the most difficult and time-consuming 
part of the thesis, but after trial and error I managed to get the codes implemented. The 
early results even lead to partial rewrite of the segmentation methods, because we noticed 
that the segmentation works better with bigger matrix sizes. 
The algorithms of the segmentation methods do not take the spatial distribution 
of the voxels into account. Thus, the segmented area can spread or fragment, making the 
region of interest distorted.  
The evaluation of segmentation methods gave important information about the 
behavior of the four selected segmentation methods. The work brought out some prob-
lematic points, but also promising results of usability of the segmentation methods. 
In conclusion, with proper settings the automated segmentation is a valuable tool 
for searching the regions of interest. Presumably, the quality of the automated segmenta-
tion will improve in the future with faster and more accurate software technology.
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APPENDIX A: THE MATLAB CODE 
 
n=256; 
pix_size=0.24; 
vol=15; %REMEMBER TO CHANGE! Must match with the volume of the tumor 
  
% Read the ROI-mask: 
fid1=fopen('C:\roiTest3\mask_15ML_168H_TH20.roi'); 
mask=zeros(n,n,n); 
for i=1:n 
 mask(:,:,i)=fread(fid1,[n n],'ushort'); 
end 
fclose(fid1); 
  
% Read the phantom corresponding to the ROI-mask: 
fid2=fopen('C:\roiTest3\ncat_168h_15ml_256.map'); 
phantom=zeros(n,n,n); 
for i=1:n 
 phantom(:,:,i)=fread(fid2,[n n],'ushort'); 
end 
fclose(fid2); 
  
% The tumor is the maxmimum value of the  
max_val=-1/eps; 
for k=1:n 
  for j=1:n 
    for i=1:n 
      if (phantom(i,j,k)>max_val) 
        max_val=phantom(i,j,k); 
      end 
    end 
  end 
end 
  
% The phantom does not include anything else but the tumor data. 
% Because the phantom has been interpolized, the tumor must be  
% thresholded a little to get the proper volume. 
% -- 
% The optimal threshold can be found with the help of the volume 
% adjusted at the beginning of the script. 
t_best=-1; %optimi-threshold 
vol_err_best=1/eps; 
for t=100:-1:1 
  curr_vol=0; 
  for k=1:n 
    for j=1:n 
      for i=1:n 
        if (phantom(i,j,k)>(t/100)*max_val) 
          curr_vol=curr_vol+pix_size*pix_size*pix_size; 
        end 
      end 
    end 
  end 
  if (abs(curr_vol-vol)<vol_err_best) 
    vol_err_best=abs(curr_vol-vol); 
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    t_best=t; 
  end 
end 
  
% Segmentation of the tumor with the optimal threshold value: 
phantom_tumor=zeros(n,n,n); 
for k=1:n 
  for j=1:n 
    for i=1:n 
      if (phantom(i,j,k)>(t_best/100)*max_val)  
        phantom_tumor(i,j,k)=1; 
      end 
    end 
  end 
end 
  
% Find the ROI-slices:  
for g = 1:length(phantom_tumor(:,:,:)) 
     
    slices = find(phantom_tumor(:,:,g) == 1); 
    if size(slices) ~= 0; 
      slice_numbers(g) = g;   
    end 
     
end 
     
ROI_slices = find(slice_numbers); 
  
% ------------------------------------------------ 
% DSC part 
pic_info_dsc = zeros(n,n,n); 
for D = 1:length(ROI_slices) 
% Turn mask into binary form 
maskin_osa = mask(:,:,ROI_slices(D));    for m = 1:n*n; 
        if maskin_osa(m) > 0 
        maskin_osa(m) = 1;  
        else 
        maskin_osa(m) = 0; 
        end 
    end 
  
fantomin_osa = phantom_tumor(:,:,ROI_slices(D)); 
  
% Intersection: 
osien_leikkaus = maskin_osa + fantomin_osa; 
    for f = 1:n*n; 
        if maskin_osa(f) ~= fantomin_osa(f) 
        osien_leikkaus(f) = 0;  
        end 
    end 
    
leikkauspikselit = find(osien_leikkaus); 
leikkaus_lkm = length(leikkauspikselit); 
leikkaus_numero(D) = leikkaus_lkm; 
  
maski_pikselit = find(maskin_osa); 
maski_lkm = length(maski_pikselit); 
  
fantomi_pikselit = find(fantomin_osa); 
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fantomi_lkm = length(fantomi_pikselit); 
  
yhdiste_lkm = fantomi_lkm + maski_lkm; 
yhdiste_numero(D) = yhdiste_lkm; 
  
pic_info_dsc(:,:,ROI_slices(D)) = osien_leikkaus; 
  
end 
  
kaikki_leikkaukset = sum(leikkaus_numero); 
kaikki_yhdisteet = sum(yhdiste_numero); 
DSC = (2*kaikki_leikkaukset)/kaikki_yhdisteet 
  
% -------------------------------------------------- 
% CE part 
 
pic_info_ce = zeros(n,n,n); 
for X = 1:length(ROI_slices) 
     
    PCE = zeros(256,256);  
    NCE = zeros(256,256); 
     
    CE_maskin_osa = mask(:,:,ROI_slices(X)); 
    for q = 1:n*n; 
        if CE_maskin_osa(q) > 0 
        CE_maskin_osa(q) = 1;  
        else 
        CE_maskin_osa(q) = 0; 
        end 
    end 
  
    CE_fantomin_osa = phantom_tumor(:,:,ROI_slices(X)); 
      
for s = 1:n*n     
if (CE_maskin_osa(s) ~= CE_fantomin_osa(s)) && (CE_maskin_osa(s) 
== 1) 
    PCE(s) = 1; 
    else if (CE_maskin_osa(s) ~= CE_fantomin_osa(s)) &&     
    (CE_maskin_osa(s) == 0) 
    NCE(s) = 1; 
    end 
    end 
end 
  
PCE_pikselit = find(PCE); 
PCE_lkm = length(PCE_pikselit); 
PCE_luku(X) = PCE_lkm; 
  
NCE_pikselit = find(NCE); 
NCE_lkm = length(NCE_pikselit); 
NCE_luku(X) = NCE_lkm; 
  
pic_info_ce(:,:,ROI_slices(X)) = PCE+NCE; 
  
CE_fantomin_koko = find(CE_fantomin_osa); 
VoS = length(CE_fantomin_koko); 
VoS_luku(X) = VoS; 
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end 
  
koko_PCE = sum(PCE_luku); 
koko_NCE = sum(NCE_luku); 
koko_VoS = sum(VoS_luku); 
  
PCE_prosentit = (koko_PCE/koko_VoS)*100 
NCE_prosentit = (koko_NCE/koko_VoS)*100 
  
CE = ((koko_PCE+koko_NCE)/koko_VoS)*100 
  
% ------------------------------------------ 
% Image formation: 
% The position of the tumor varies between the data sets, so the  
% coordinates have to be adjusted for every data set individually. 
% The optimal coordinates have been already searched.  
% There is a list below: 
% -- 24h --  
% 11ml 
% middleslice = 169; 
% Y = [81:111]; 
% X = [114:145]; 
% 16ml 
% middleslice = 180; 
% Y = [91:123]; 
% X = [115:144]; 
% 90ml 
% middleslice = 188; 
% Y = [92:125]; 
% X = [109:147]; 
  
% -- 168h -- 
% 5ml 
% middleslice = 173; 
% Y = [85:120]; 
% X = [115:148]; 
% 15ml 
 middleslice = 188; 
 Y = [89:123]; 
 X = [109:143]; 
% 90ml 
% middleslice = 187; 
% Y = [88:123]; 
% X = [108:143]; 
  
A = phantom_tumor(:,:,middleslice); 
phantom_pic = A(Y,X); 
B = mask(:,:,middleslice); 
mask_pic = B(Y,X); 
C = pic_info_dsc(:,:,middleslice); 
DSC_pic = C(Y,X); 
D = pic_info_ce(:,:,middleslice); 
CE_pic = D(Y,X); 
  
% After the proper coordinates have been adjusted, the four  
% different data sets are combined into one image: 
PIC = [phantom_pic mask_pic DSC_pic CE_pic]; 
figure, imshow(PIC); 
